Company

Company Drug

Zhongsheng Files China Trial Application to Expand Onradivir into High‑Risk Influenza A Patients, Broadening Its First‑in‑Class PB2 Inhibitor Franchise

Zhongsheng Pharmaceutical (SHE: 002317) announced that it has submitted a clinical trial application in China...

Company Deals

PegBio Signs R&D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long‑Acting Delivery for Metabolic Diseases

Fineline Cube Sep 3, 2026

PegBio Co., Ltd. (HKG: 2565) announced that it has entered into a material transfer agreement...

Company Drug

Cutia Therapeutics’ CU‑20101 BLA Accepted by NMPA for Moderate to Severe Glabellar Lines, Advancing a Safer Botulinum Toxin Type A

Fineline Cube Sep 3, 2026

Cutia Therapeutics (HKG: 2487) announced that the Biologics License Application (BLA) for CU‑20101 has been...

Company Deals

Biocytogen Signs Non‑Exclusive Nanobody Licensing Deal with Qilu Pharmaceutical for Innovative Neurological Drug R&D

Fineline Cube Sep 3, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315; SHA: 688796) announced that it has signed a...

Company Drug

Haixi Pharma Completes Phase I of Oral HX9428 in nAMD with Visual Gains, Files IND for DME Phase IIa as FDA Fast Track Asset Expands

Fineline Cube Sep 3, 2026

Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced dual clinical progress updates for HX9428, its...

Company Drug

Hansoh’s HS‑20093 Risvutatug Rezetecan NDA Accepted by NMPA for Small Cell Lung Cancer After First Global Phase III OS Win for a B7‑H3 ADC

Fineline Cube Sep 3, 2026

Hansoh Pharmaceutical (HKG: 3692) announced that the marketing authorization application for its independently developed HS‑20093...

Company Drug

Ocumension Completes Enrollment in China Phase III Trial of OT‑211 for Dry Eye Disease, Aligned with Global COMET Pivotal Program

Fineline Cube Sep 3, 2026

Ocumension Therapeutics (HKG: 1477) announced that all subjects have been enrolled as scheduled in the...

Company Deals PIC

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.

Fineline Cube Sep 3, 2026

Medtronic (NYSE: MDT) announced a strategic partnership with Cornerstone Robotics, including a strategic investment of...

Company Deals

HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL‑A830, Its First‑in‑Class KRAS ATTC Cancer Candidate

Fineline Cube Sep 3, 2026

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced today that its subsidiary, HUTCHMED Limited, has...

Company Drug

Everest Medicines Wins NMPA Approval for Etripamil Nasal Spray Cardamyst in PSVT, Bringing ER‑Free Arrhythmia Care to Greater China

Fineline Cube Sep 3, 2026

Everest Medicines (HKG: 1985) announced today that its etripamil nasal spray has received marketing approval...

Company Drug

GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots

Fineline Cube Sep 2, 2026

GlaxoSmithKline Plc (GSK, NYSE: GSK) announced positive Phase II clinical data for its mRNA seasonal...

Company Drug PIC

Allergan Aesthetics’ SKINVIVE by Juvéderm Wins NMPA Approval for Perioral Wrinkles, Backed by 93.4% POLSS Responder Rate

Fineline Cube Sep 2, 2026

Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced that its SKINVIVE by Juvéderm, an injectable...

Company Drug

Beijing Huasu Wins NMPA Clinical Trial Approval for Methylphenidate ER Chewable Tablets, First Domestic Generic for ADHD Treatment

Fineline Cube Sep 2, 2026

Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of Beijing Centergate Technologies (SHE: 000931), has received...

Company Drug

Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis

Fineline Cube Sep 2, 2026

Novartis (NYSE: NVS) announced positive topline results from its Phase III REMODEL-1/-2 clinical trials of...

Company Drug

SYS6010 Earns Third NMPA Breakthrough Therapy Designation, Advancing CSPC Innovation Pharmaceutical’s EGFR ADC in R/M HNSCC

Fineline Cube Sep 2, 2026

CSPC Innovation Pharmaceutical Co., Ltd. (SHE: 300765) announced that SYS6010, its epidermal growth factor receptor...

Company Deals

Huadong Medicine and Heidelberg Pharma Expand ADC Collaboration to Advance Next-Generation Bispecific Conjugates

Fineline Cube Sep 2, 2026

Huadong Medicine (SHE: 000963) announced that it signed a new additional collaboration agreement with its...

Company Deals

Sino Biopharmaceutical’s CTTQ Grants Cipla Rights to TQB2102 HER2 ADC in Emerging Markets for Up to USD 123 Million

Fineline Cube Sep 2, 2026

Sino Biopharmaceutical (HKG: 1177) announced that its subsidiary, Chia Tai Tianqing (CTTQ), entered into an...

Company Drug

GenSci161 Wins NMPA Clinical Trial Acceptance for CTD-ILD, Expanding Bispecific Antibody Pipeline of Changchun High & New Technology

Fineline Cube Sep 2, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its novel bispecific...

Company Deals PIC

Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal

Fineline Cube Sep 2, 2026

Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that...

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026

China’s Shanghai RAAS (SHE: 002252) announced that its candidate SR604 has been included by the...

Company

Zhongsheng Files China Trial Application to Expand Onradivir into High‑Risk Influenza A Patients, Broadening Its First‑in‑Class PB2 Inhibitor Franchise

PegBio Signs R&D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long‑Acting Delivery for Metabolic Diseases

Cutia Therapeutics’ CU‑20101 BLA Accepted by NMPA for Moderate to Severe Glabellar Lines, Advancing a Safer Botulinum Toxin Type A

Biocytogen Signs Non‑Exclusive Nanobody Licensing Deal with Qilu Pharmaceutical for Innovative Neurological Drug R&D

Haixi Pharma Completes Phase I of Oral HX9428 in nAMD with Visual Gains, Files IND for DME Phase IIa as FDA Fast Track Asset Expands

Hansoh’s HS‑20093 Risvutatug Rezetecan NDA Accepted by NMPA for Small Cell Lung Cancer After First Global Phase III OS Win for a B7‑H3 ADC

Ocumension Completes Enrollment in China Phase III Trial of OT‑211 for Dry Eye Disease, Aligned with Global COMET Pivotal Program

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.

HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL‑A830, Its First‑in‑Class KRAS ATTC Cancer Candidate

Everest Medicines Wins NMPA Approval for Etripamil Nasal Spray Cardamyst in PSVT, Bringing ER‑Free Arrhythmia Care to Greater China

GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots

Allergan Aesthetics’ SKINVIVE by Juvéderm Wins NMPA Approval for Perioral Wrinkles, Backed by 93.4% POLSS Responder Rate

Beijing Huasu Wins NMPA Clinical Trial Approval for Methylphenidate ER Chewable Tablets, First Domestic Generic for ADHD Treatment

Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis

SYS6010 Earns Third NMPA Breakthrough Therapy Designation, Advancing CSPC Innovation Pharmaceutical’s EGFR ADC in R/M HNSCC

Huadong Medicine and Heidelberg Pharma Expand ADC Collaboration to Advance Next-Generation Bispecific Conjugates

Sino Biopharmaceutical’s CTTQ Grants Cipla Rights to TQB2102 HER2 ADC in Emerging Markets for Up to USD 123 Million

GenSci161 Wins NMPA Clinical Trial Acceptance for CTD-ILD, Expanding Bispecific Antibody Pipeline of Changchun High & New Technology

Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

You Missed

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo

Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib